S

Sun Pharmaceutical Industries Limited

SUNPHARMANSE
Market snapshot · 2026-08-10 20:56 UTC

1,944.40

₹-0.60 (-0.03%)

MARKET CAP

₹4.67L Cr

STOCK P/E

38.6x

52W HIGH

₹2,046.90

52W LOW

₹1,548.00

BOOK VALUE

₹348.31

EPS

₹50.38

ROE

SECTOR

Industrials

DEBT/EQUITY

5.52

VOLUME

17.27L

P/B RATIO

5.58x

PEG RATIO

1.04

Sector

Industrials

Themes

Renewable Energy Equipment & Services
D
Dividend
E
Earnings
₹1,990.50₹1,885.96₹1,781.42₹1,676.88₹1,572.34VolumeEDEEDEAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Sun Pharmaceutical Industries is a generic pharmaceutical company selling branded and generic formulations, APIs, and specialty medicines. India and international formulations drive revenue, supported by generic tablets, injectables, inhalers, and topical products. Recent results exceeded expectations, with revenue increasing about 10%, supporting the reported 11.9% annual growth. However, potential 100% US tariffs threaten export economics and could pressure future margins. Margins remain stable, while profit growth of 5% trails revenue growth, indicating limited earnings conversion. ROE is unavailable, but debt/equity of 5.52 implies significant leverage, which can magnify financial risk and affect shareholder returns. At 38.6 times earnings, the shares appear rich relative to 5% profit growth. The key open question is whether specialty medicines and international formulations can offset US trade-policy risks.

Valuation Metrics

Trading 16.7% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.49). Confidence: 86%.

Live forward EPS implies next-12-month EPS of ₹64.53. Applying the stock's normalized valuation corridor produces a fair range of ₹1,930.74 to ₹2,269.52, with base value near ₹2,135.30 (+9.8% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Inside normalized range

Forward EPS

₹64.53

Forward P/E

30.1x

Base Fair Value

₹2,135.30

Fair Range

₹1,930.74 - ₹2,269.52

Upside To Base

+9.8%

Estimate Source

Live forward EPS

Growth Estimate

+27.4%

P/E
Strongly Overvalued

5Y Average

26.66

Current

38.61

Overvalued

35.17

Undervalued

29.92

EV/EBITDA
Strongly Overvalued

5Y Average

18.24

Current

26.41

Overvalued

23.26

Undervalued

12.92

P/S
Strongly Overvalued

5Y Average

5.38

Current

7.79

Overvalued

6.86

Undervalued

3.81

Peers & Comparison

Sector: Industrials · Theme: Renewable Energy Equipment & Services

Renewable Energy Equipment & Services Peers8 peers
Avg P/E: 34.5x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
FUJIYAMA POWER SYSTEMS L
UTLSOLARRenewable Energy Equipment & Services
+87.5%11.5%
39.0x
Fair
+13% vs avg
+87.1%
WAAREE ENERGIES LIMITED
WAAREEENERRenewable Energy Equipment & Services
+79.2%12.7%
20.4x
Undervalued
-41% vs avg
-12.7%
SUZLON ENERGY LIMITED
SUZLONRenewable Energy Equipment & Services
+22.5%18.1%
20.7x
Undervalued
-40% vs avg
-24.0%
SAATVIK GREEN ENERGY LTD
SAATVIKGLRenewable Energy Equipment & Services
+74.9%7.9%
14.1x
Undervalued
-59% vs avg
-3.9%
AZAD ENGINEERING LIMITED
AZADRenewable Energy Equipment & Services
+28.5%21.9%
123.4x
Premium
+258% vs avg
+67.5%
STRLNG & WIL REN ENE LTD
SWSOLARRenewable Energy Equipment & Services
-9.7%-3.9%
-25.4%
GK ENERGY LIMITED
GKENERGYRenewable Energy Equipment & Services
+35.2%11.9%
12.3x
Undervalued
-64% vs avg
-18.4%
INSOLATION ENERGY LIMITED
INARenewable Energy Equipment & Services
+100.1%9.3%
11.9x
Undervalued
-66% vs avg
+14.2%
WHY THESE PEERS

Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹15.18K CrJun 2026

Latest net profit

₹2.90K CrJun 2026

Latest EPS

₹12.10Jun 2026

Net margin

23.4%Jun 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.0%7.0%14.0%21.0%28.0%0.00 Cr4.00K Cr8.00K Cr12.00K Cr16.00K Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.00 Cr4.00K Cr8.00K Cr12.00K Cr16.00K Cr₹0₹4₹8₹12₹16
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr4.00K Cr8.00K Cr12.00K Cr16.00K Cr

Latest reported period: Jun 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2025Mar 20260.00 Cr30.00K Cr60.00K Cr90.00K Cr1.20L Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

Sales

₹15,184 Cr

+18.5%

Net Profit

₹2,895 Cr

+34.6%

EBITDA

₹4,937 Cr

+24.4%

EPS

₹12.10

+34.4%
MetricMar 2025Jun 2025Dec 2025Mar 2026Jun 2026
Sales12,81613,78615,46914,56015,184
Expenses10,05510,41411,40711,80811,627
Operating Profit2,7613,3724,0622,7523,557
OPM %21.54%24.46%26.26%18.9%23.43%
Other Income613464579458724
Interest49757886100
Depreciation664701732775739
Profit before tax3,2543,1734,2273,5514,099
Tax %33.61%27.43%19.54%23.31%28.98%
Net Profit2,1502,2793,3692,7142,895
EPS in Rs9.009.5014.0011.3012.10

All values in ₹ Crores unless otherwise stated. Source: Company filings.

Shareholding Pattern

HolderMar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Promoters61.49%61.49%61.49%61.67%62.00%
Public34.92%36.66%35.19%35.56%35.24%
Others3.59%1.85%3.32%2.77%2.76%
Mar 2026
Promoters
Public
Others

Events Timeline

Concall Transcript - FY2027

Jul 14, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

May 29, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

May 27, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

May 25, 2026PDFKnowledge Base Open

Concall Transcript - FY2027

May 22, 2026PDFKnowledge Base Open